SVB Leerink Maintains Outperform on Forma Therapeutics Hldgs, Lowers Price Target to $54
SVB Leerink analyst Andrew Berens maintains Forma Therapeutics Hldgs (NASDAQ:FMTX) with a Outperform and lowers the price target from $65 to $54.
Forma Therapeutics Highlights Presentation Of New Phase 1 Data On Etavopivat At European Hematology Association Congress
Clinical results demonstrated durable improvement in hematologic and hemolytic markers, supporting the potential for improvement of red blood cell functional health in those with sickle cell disease
Initial results from
The Week Ahead In Biotech: ASCO Presentations Front And Center, FDA Decisions Due For Scynexis, Liminal And Alkermes
After having declined through the first half of the week, biotech stocks staged a recovery to close higher in the trading week ended May 28. Broader market sentiment and company-specific news flow dictated stock moves during the week.
The Daily Biotech Pulse: CorMedix Slumps On Delay In Resubmission of DefenCath NDA, Apellis Awaits FDA Decision, Vera Therapeutics Debuts
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs May 13)
Earnings Scheduled For May 14, 2021
Companies Reporting Before The Bell
• Sogou (NYSE:SOGO) is projected to report earnings for its first quarter.
• Sohu.com (NASDAQ:SOHU) is estimated to report earnings for its first quarter.
The Week Ahead In Biotech (May 9-15): Heron, Apellis FDA Decisions, Presentations and Earnings
Biotech stocks came under pressure in the week ended May 7 as traders digested a slew of earnings news flow and a handful of clinical trial readouts. COVID-19 vaccine stocks came under pressure following the U.S.